Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

被引：0
|
作者：
Yu, Y. [1 ]
Elmeliegy, M. [1 ]
Litton, J. K. [2 ]
Tudor, I. C. [3 ]
Czibere, A. [4 ]
Zheng, J. [5 ]
Wang, D. D. [1 ]
机构：
[1] Pfizer Inc, Oncol, La Jolla, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
[3] Pfizer Inc, Biostat, San Francisco, CA USA
[4] Pfizer Inc, Oncol, Cambridge, MA USA
[5] Pfizer Inc, Oncol, Collegeville, PA USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305P
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [1] Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials
    Elmeliegy, M.
    Yu, Y.
    Litton, J. K.
    Turner, N. C.
    Czibere, A.
    Wilson, G. G.
    Tudor, I. C.
    Zheng, J.
    Wang, D. D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials
    Elmeliegy, Mohamed
    Yu, Yanke
    Litton, Jennifer K.
    Czibere, Akos
    Wilson, Gary G.
    Tudor, Lulia Cristina
    Zheng, Jenny
    Wang, Diane D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (10): : 1334 - 1343
  • [3] Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and GermlineBRCA1/2Mutations in the EMBRACA Trial
    Yu, Yanke
    Elmeliegy, Mohamed
    Litton, Jennifer K.
    Tudor, Lulia Cristina
    Czibere, Akos
    Zheng, Jenny
    Wang, Diane D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (10): : 1324 - 1333
  • [4] Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
    Hurvitz, Sara A.
    Gocalves, Anthony
    Rugo, Hope S.
    Lee, Yung-Hun
    Fehrenbacher, Louis
    Mina, Lida A.
    Diab, Sami
    Blum, Joanne L.
    Chakrabarti, Jayeta
    Elmeliegy, Mohamed
    DeAnnuntis, Liza
    Gauthier, Eric
    Czibere, Akos
    Tudor, Iulia Cristina
    Quek, Ruben G. W.
    Litton, Jennifer K.
    Ettl, Johannes
    ONCOLOGIST, 2020, 25 (03): : E439 - E450
  • [5] PARP Inhibitor for advanced BRCA1/2 Breast Cancer Talazoparib: Prolonging progression-free Survival without Chemotherapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 397 - 397
  • [6] EMBRACA: Efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: A regional analysis
    Mina, L.
    Lee, K-H
    Goncalves, A.
    Woodward, N.
    Hurvitz, S. A.
    Diab, S.
    Yerushalmi, R.
    Goodwin, A.
    Moreira Costa Zorzetto, M.
    Kim, S-B
    Czibere, A.
    Tudor, I. C.
    Gauthier, E.
    Litton, J. K.
    Ettl, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [7] Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial
    Hurvitz, S. A.
    Rugo, H. S.
    Ettl, J.
    Martin, M.
    Roche, H.
    Lee, K-H.
    Goodwin, A.
    Usari, T.
    Lanzalone, S.
    Guenzel, C. A.
    Blum, J.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S482 - S482
  • [8] Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
    Lee, Kyung-Hun
    Sohn, Joohyuk
    Goodwin, Annabel
    Usari, Tiziana
    Lanzalone, Silvana
    Im, Seock-Ah
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 1084 - 1095
  • [9] Breast cancer survival of young patients: The impact of BRCA1/2 germline mutations
    Schmidt, M. K.
    Van den Broek, A. J.
    Tollenaar, R. A. E. M.
    Van Leeuwen, F. E.
    Van 't Veer, L. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S474 - S474
  • [10] Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    Litton, J. K.
    Hurvitz, S. A.
    Mina, L. A.
    Rugo, H. S.
    Lee, K-H
    Goncalves, A.
    Diab, S.
    Woodward, N.
    Goodwin, A.
    Yerushalmi, R.
    Roch, H.
    Im, Y-H
    Eiermann, W.
    Quek, R. G. W.
    Usari, T.
    Lanzalone, S.
    Czibere, A.
    Blum, J. L.
    Martin, M.
    Ettl, J.
    ANNALS OF ONCOLOGY, 2020, 31 (11) : 1526 - 1535
12345